幹細胞療法市場：タイプ別、細胞源別、治療用途別、エンドユーザー別、予測（2024年～2030年）

世界の幹細胞療法の市場規模は、2023年に4億3,983万米ドルとなり、2024年には4億9,323万米ドルに達し、CAGR12.88％で2030年には10億2,744万米ドルに達すると予測されています。

幹細胞療法とは、損傷を受けた組織や臓器を置換・修復するために幹細胞を医療利用することを指します。この治療法は、身体の修復メカニズムを刺激することで、パーキンソン病、アルツハイマー病、糖尿病、心臓病など様々な病気の治療に重要です。幹細胞は、生後間もない時期や成長過程において、体内で様々な種類の細胞を発生させる可能性があります。慢性疾患の蔓延や再生治療に対する政府の積極的な取り組みは、世界的に幹細胞療法の必要性を高めています。しかし、高コスト、厳しい規制、承認プロセスに伴う懸念は、主要企業にとって大きな課題です。企業各社は、この領域で機敏に対応するため、政府によって課された厳格な基準を遵守しようとしています。さらに、再生医療における主な発展と継続的な研究開発活動は、主要企業の将来的な事業拡大に寄与しています。

タイプ：慢性疾患治療における同種・自己幹細胞療法の使用増加

同種移植は、ドナーから別のレシピエントに幹細胞を移植する治療法です。この治療法は、遺伝性疾患の場合など、治療に適さない細胞を持つ患者の条件下で好まれることが多いです。また、容易に入手できるため、治療が迅速に行えるという利点もあります。一方、自己幹細胞療法は、患者の骨髄、脂肪組織、血液から採取した幹細胞を用います。このタイプの治療法は、患者の体から採取された細胞であるため、免疫拒絶反応のリスクが低いです。

細胞源：組織リモデリングと組織修復におけるAD-MSCsとBM-MSCsの採用増加

脂肪組織由来間葉系幹細胞（AD-MSCs）は、一般に体脂肪として知られる脂肪組織から得られます。これらの細胞は、その入手が比較的容易であることから、大きな関心を集めています。AD-MSCsの抽出は、他の供給源よりも侵襲的な処置を必要とせず、脂肪吸引による局所麻酔下で行うことができます。AD-MSCは複数の細胞型に分化し、成長因子を分泌し、免疫応答を調節することから、様々な治療アプローチに用いられています。同時に、骨髄由来間葉系幹細胞（BM-MSCs）は骨髄、典型的には骨盤の腸骨稜から採取されます。BM-MSCは、骨、軟骨、脂肪組織に分化する可能性が知られており、広く研究されている幹細胞のひとつです。BM-MSCはまた、強力な免疫調節特性を有しており、自己免疫疾患の治療や骨髄移植における生着支援の有力な候補となっています。一方、胎盤・臍帯由来間葉系幹細胞（PC-UC-MSCs）は、出産後の胎盤と臍帯から得られます。これらの細胞は、AD-MSCsやBM-MSCsのような成体幹細胞に比べ、非侵襲的に採取でき、増殖率も高いです。

治療用途：様々な治療分野における再生医療の人気の高まり

幹細胞は、心筋梗塞やうっ血性心不全を含む様々な心血管系疾患の治療において、画期的な選択肢として検討されています。幹細胞を利用した処置は、損傷した心臓組織を再生し、心臓機能を改善し、心臓細胞の修復を促す可能性を秘めています。ループスや関節リウマチを含む疾患では、硬化症幹細胞療法は疾患プロセスを修正し、免疫バランスを回復させることができます。これらの細胞はT細胞応答を調節することができ、ある種の自己免疫疾患の治療に用いられてきました。変形性関節症、筋ジストロフィー、その他の筋骨格系障害などの症状に対して、幹細胞療法は軟骨、骨、筋肉組織の再生に有望です。この治療法は、痛みを軽減し、機能を改善し、関節置換術のような侵襲的な治療を遅らせたり、その必要性を回避することを目的としています。幹細胞療法のアルツハイマー病などの神経疾患の治療への可能性は、神経細胞やグリア細胞を保護、修復、置換する能力にあります。幹細胞は、創傷や傷害の治癒を促進する重要な能力を示しています。MSCを創傷治療に用いることで、これらの細胞は皮膚組織の再生を促進し、瘢痕を減らし、治癒期間を改善することができます。これは特に、火傷患者、糖尿病性潰瘍の患者、創傷治癒の遅い患者にとって重要です。

エンドユーザー：効果的で安全、標準化された治療結果を提供する学術・研究センターや病院での幹細胞療法の使用増加

学術・研究開発センターは幹細胞科学を発展させる上で極めて重要であり、疾患研究、医薬品開発、画期的な治療法の開発などを推進するために様々な種類の幹細胞を必要としています。このような機関は先駆的な研究に大きく貢献し、幹細胞応用の革新の温床となっています。一方、外来手術センター（ASC）は、ある種の外来幹細胞治療の場を提供しています。これらのセンターは、病院よりもリソースを必要としないため、患者や保険者にとって費用対効果の高い選択肢となります。病院や診療所は、特に複雑で急性の疾患に対する幹細胞治療の主要な場であることに変わりはありません。白血病やリンパ腫などの疾患に対する造血幹細胞移植（HSCT）や、様々な再生医療への応用を含む、幅広い幹細胞治療へのニーズは、病院や診療所が対応する患者の多様性によって生み出されています。幹細胞治療の開発と商業化において、バイオ製薬会社は重要な役割を担っています。彼らは、新薬の発見や再生医療の開発といった研究開発目的のために幹細胞を購入するだけでなく、幹細胞株を用いて大規模な治療製品を製造する製造目的でも幹細胞を購入しています。幹細胞治療に対するバイオファーマの関心は、既存の医薬品よりも優れた治療効果をもたらす革新的な治療法を探し続けていることと一致しています。バイオ製薬会社は幹細胞治療の開発と商業化に取り組んでいます。幹細胞を購入するのは、新薬の発見や再生医療の開発を目的とした研究開発目的だけでなく、幹細胞株を用いて大規模な治療製品を製造する製造目的でもあります。

地域別の洞察

米国やカナダなどの国々では、ヘルスケアのインフラが発達しており、慢性疾患の罹患率が高いことから、幹細胞療法のような革新的な治療法へのニーズが高まっています。顧客の購買行動は、特に再生医療などの分野で、新しいヘルスケア技術を採用する傾向が強いことを反映しています。幹細胞特許におけるこの地域の主要な地位が、強固で進化する治療市場を支えていることは、多大な研究投資と活動によって証明されています。欧州連合（EU）は、ドイツ、英国、フランスなどの国々が研究や臨床応用に重点を置いており、幹細胞療法の多様な空間を提示しています。同時に、中東・アフリカでは、ヘルスケア改善への莫大な投資と先進医療への需要の高まりにより、幹細胞療法への関心が急増しています。Dubai Cell Therapy and Regenerative Medicine Frameworkのようなイニシアチブは、この地域を幹細胞療法における医療ツーリズムのハブとして位置づけることを目指しています。一方、アジアでは、中国、日本、インドといった国々が幹細胞治療の急速な市場拡大を反映しており、政府の支援政策によって研究とイノベーションが盛んに行われる環境となっています。日本や中国は、再生医療製品の迅速な承認取得という先進的な規制を導入しているため、これらの国々が幹細胞療法を採用する主要な空間となっています。インドでは、ヘルスケアのインフラが整備され、公的・私的研究資金が増加し、幹細胞治療の利用拡大や研究開発へのシフトが進んでいます。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは幹細胞療法市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、幹細胞療法市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発・イノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.幹細胞療法市場の市場規模・予測は？

2.幹細胞療法市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.幹細胞療法市場の技術動向と規制枠組みは？

4.幹細胞療法市場における主要ベンダーの市場シェアは？

5.幹細胞療法市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で変性疾患やがんの罹患率が上昇
    • 世界中で幹細胞療法に関する政府の取り組みが増加
    • 幹細胞療法センターとクリニックの拡張
  • 抑制要因
    • 幹細胞療法の実行に伴う困難
  • 機会
    • 幹細胞療法の継続的な進歩
    • 幹細胞療法・治療法の販売・臨床試験の承認が急増
  • 課題
    • 幹細胞療法の倫理的・安全性の問題
• 市場セグメンテーション分析
  • タイプ：慢性疾患治療における同種・自己移植幹細胞療法の使用増加
  • 細胞源：組織リモデリングと組織修復におけるAD-MSCとBM-MSCの採用増加
  • 治療用途：さまざまな治療領域での再生医療の人気の高まり
  • エンドユーザー：効果的で安全かつ標準化された治療結果を提供する学術研究センターや病院での幹細胞療法の使用増加
• 市場動向分析
  • 厳格な幹細胞療法に基づく調査イニシアチブ、進化する規制枠組み、先進的な治療法に対する需要の増加が、南北アメリカにおける市場を活性化
  • 政府の資金援助とアジア太平洋諸国における医療ツーリズムの実践による導入の増加に支えられた幹細胞治療の進歩
  • 政府の資金援助を受けた学術機関とバイオテクノロジー企業の強力なネットワークが、欧州・中東・アフリカにおける幹細胞研究と商業化を加速
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 幹細胞療法市場：タイプ別

• 同種異系幹細胞療法
• 自己幹細胞療法

第7章 幹細胞療法市場：細胞源

• 脂肪組織由来MSC
• 骨髄由来MSC
• 胎盤/臍帯由来MSC

第8章 幹細胞療法市場：治療用途別

• 心臓血管疾患の手術
• 炎症性疾患・自己免疫疾患
• 筋骨格障害
• 神経学的障害
• 整形外科とリウマチ
• 傷と負傷

第9章 幹細胞療法市場：エンドユーザー別

• 学術研究センター
• 外来手術センター
• バイオテクノロジー・製薬会社
• 病院・クリニック

第10章 南北アメリカの幹細胞療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の幹細胞療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの幹細胞療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析（2023年）
• FPNVポジショニングマトリックス（2023年）
• 競合シナリオ分析
  • 富士フイルム、細胞治療の生産に2億米ドルを投資
  • メソブラスト、FDAの拒否後SR-aGVHD試験の協力を開始
  • セレクタ・バイオサイエンス、カルテシアン・セラピューティクスとの合併を発表
  • タカラバイオ、Fondazione Telethon ETSとRetroNectinのライセンス契約を締結
  • バイエル、世界規模で再生医療を推進するため初の細胞治療製造施設を開設
  • ノボノルディスク財団、細胞治療工場建設に1億3,500万米ドルを投資
  • BioLineRx、多発性骨髄腫患者の造血幹細胞の採取とその後の自家移植を目的としたフィルグラスチム（G-CSF）との併用によるAPHEXDA（モチキサフォルチド）のFDA承認を発表
  • BlueRock Therapeuticsとbit.bioが、制御性T細胞（Treg）ベースの治療法の発見と製造に関する協力とオプション契約を発表
  • StemCyte、最先端の米国免疫細胞療法企業と協力契約を締結し、同種改変細胞療法用の医薬品製造原料を供給
  • CIRM、幹細胞・遺伝子治療調査に8,900万米ドルを投資
  • ブリストルマイヤーズスクイブ、ウイルスベクター生産のための米国新製造施設の開設により細胞治療能力を強化
  • ノボノルディスク、ボストン大都市圏での研究開発拠点を拡大
  • ガルーダ・セラピューティクス、既製の血液幹細胞技術プラットフォームの発展に向けて6,200万米ドルのシリーズB資金調達を確保
  • BioCardiaとCellProtheraは、欧州での急性心筋梗塞治療のためのProtheraCytesの開発と患者への早期アクセスの可能性に向けて協力関係を強化
  • ReLive Biotechnologies Ltd.がCo.Don AGの資産買収とSHC主導のシリーズ A資金調達を完了し、再生療法の世界企業になるという野心をさらに推進

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. STEM CELL THERAPY MARKET DYNAMICS
• FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 67. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 68. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 69. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 70. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 71. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 72. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 73. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 74. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 75. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 81. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 82. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 83. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 86. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 91. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 94. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 95. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 96. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 104. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 106. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 110. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 111. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 114. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 115. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 116. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 117. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 118. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 119. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 122. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 123. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 124. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 125. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 126. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 127. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 133. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 134. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 135. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 138. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 141. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 142. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 143. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 144. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 145. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 146. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 150. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 151. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 157. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 158. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 159. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 162. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 165. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 166. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 167. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 168. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 169. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 170. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 178. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 182. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 183. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 189. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 190. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 191. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 192. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 193. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 194. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 197. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 198. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 199. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 202. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 215. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 216. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 217. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 218. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 219. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 220. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 224. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 225. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 228. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 231. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 232. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 233. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 234. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 235. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 236. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 239. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 240. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 241. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 242. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 243. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 244. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 247. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 248. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 249. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 255. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 256. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 257. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 258. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 259. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 260. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 261. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 262. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 263. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 264. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 265. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 266. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 267. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 268. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 271. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 272. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 273. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 280. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 281. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 282. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 283. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 284. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 287. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 288. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 289. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 290. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 291. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 292. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 293. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 294. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 295. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 296. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 297. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 298. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 299. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 300. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 301. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 302. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 303. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 304. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 305. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 306. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 307. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 308. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 309. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 310. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 311. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 312. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 313. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 314. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 315. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 316. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 317. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 318. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 319. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 320. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 321. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 322. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 323. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 324. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 325. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 326. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 327. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 328. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 329. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 330. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 331. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 332. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 333. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 334. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 335. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 336. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 337. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 338. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 339. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 340. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 341. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 342. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 343. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 344. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
• TABLE 345. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
• TABLE 346. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
• TABLE 347. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 348. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 349. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 350. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 351. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
• TABLE 352. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)

[195 Pages Report] The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.

Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.

Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments

Allogeneic stem cell therapy involves the transplantation of stem cells from a donor to another recipient. This therapy is often preferred in conditions for patients with cells unsuitable for therapy, such as in cases with genetic disorders. It also allows for off-the-shelf solutions, leading to rapidness in treatment administration. On the other hand, autologous stem cell therapy uses a patient's stem cells collected from their bone marrow, adipose tissue, and blood. This type of therapy is associated with a lower risk of immune rejection since the cells are derived from the patient's body.

Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing

Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are obtained from adipose tissue, commonly known as body fat. These cells are of significant interest due to their relative ease of access. The extraction of AD-MSCs involves less invasive procedures than other sources and can be done under local anesthesia via liposuction. AD-MSCs are used in various therapeutic approaches because they differentiate into multiple cell types, secrete growth factors, and modulate immune responses. At the same time, bone marrow-derived mesenchymal stem cells (BM-MSCs) are harvested from the bone marrow, typically from the iliac crest of the pelvis. They are among the extensively studied stem cells with known potential to differentiate into bone, cartilage, and adipose tissue. BM-MSCs also have robust immunomodulatory properties, making them prominent candidates for treating autoimmune diseases and supporting engraftment in bone marrow transplantation. While, placental and umbilical cord-derived mesenchymal stem cells (PC-UC-MSCs) are obtained from the placenta and the umbilical cord following childbirth. These cells are non-invasive to collect and have a higher proliferation rate than adult stem cells, such as AD-MSCs and BM-MSCs.

Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas

Stem cells are being explored as a revolutionary option in the treatment of various cardiovascular diseases, including myocardial infarction and congestive heart failure. Procedures utilizing stem cells have the potential to regenerate damaged heart tissue, improve heart function, and stimulate the repair of cardiac cells. In diseases including lupus and rheumatoid arthritis, sclerosis stem cell therapy can modify the disease process and restore immune balance. These cells can modulate T-cell responses and have been used to treat certain autoimmune diseases. For conditions such as osteoarthritis, muscular dystrophy, and other musculoskeletal disorders, stem cell therapy is promising for regenerating cartilage, bone, and muscle tissues. The treatment aims to reduce pain, improve function, and possibly delay or avoid the need for more invasive treatments like joint replacements. Stem cell therapy's potential to treat neurological disorders such as Alzheimer's is its capacity to protect, repair, or replace neurons and glial cells. Stem cells demonstrate a significant capacity to enhance the healing of wounds and injuries. By deploying MSCs in wound care, these cells can promote the regeneration of skin tissue, reduce scarring, and improve healing times. This is particularly relevant for burn victims, patients with diabetic ulcers, or individuals who experience slow wound healing.

End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes

Academic & research centers are crucial in advancing stem cell science and require various stem cell types to propel disease study, medication development, and therapy innovation breakthroughs. These institutions significantly contribute to pioneering studies and serve as a breeding ground for innovation in stem cell applications. On the other hand, ambulatory surgical centers (ASCs) provide a setting for certain types of outpatient stem cell therapies. These centers, less resource-intensive than hospitals, offer a cost-effective alternative for patients and insurers. Hospitals and clinics remain the primary care setting for the administration of stem cell therapies, particularly for more complex and acute medical conditions. The diverse patient population they serve creates a need for a broad range of stem cell therapies, including hematopoietic stem cell transplantation (HSCT) for diseases such as leukemia and lymphoma and various regenerative medicine applications. Biopharmaceutical companies are key players in the development and commercialization of stem cell therapies. They not only purchase stem cells for R&D purposes - working on new drug discoveries and development of regenerative medicine - but also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale. Biopharma's interest in stem cell therapies corresponds with its ongoing search for innovative treatments that offer improved outcomes over existing medicines. Biopharmaceutical companies work on the development and commercialization of stem cell therapies. They purchase stem cells for R&D purposes to on new drug discoveries and the development of regenerative medicine and also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale.

Regional Insights

In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Allogeneic Stem Cell Therapy
  • Autologous Stem Cell Therapy

• Cell Source
  • Adipose Tissue-Derived MSCs
  • Bone Marrow-Derived MSCs
  • Placental / Umbilical Cord-Derived MSCs

• Therapeutic Application
  • Cardiovascular Diseases Surgeries
  • Inflammatory & Autoimmune Diseases
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Orthopedics & Rheumatoid
  • Wounds & Injuries

• End-User
  • Academic & Research Centers
  • Ambulatory Surgical Centers
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stem Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?

4. What is the market share of the leading vendors in the Stem Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
    • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
    • 5.1.1.3. Expansion of stem cell therapy centers and clinics
  • 5.1.2. Restraints
    • 5.1.2.1. Difficulties associated with performing stem cell therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in stem cell therapy
    • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
  • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
  • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
  • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
• 5.3. Market Trend Analysis
  • 5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
  • 5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
  • 5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Stem Cell Therapy Market, by Type

• 6.1. Introduction
• 6.2. Allogeneic Stem Cell Therapy
• 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

• 7.1. Introduction
• 7.2. Adipose Tissue-Derived MSCs
• 7.3. Bone Marrow-Derived MSCs
• 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases Surgeries
• 8.3. Inflammatory & Autoimmune Diseases
• 8.4. Musculoskeletal Disorders
• 8.5. Neurological Disorders
• 8.6. Orthopedics & Rheumatoid
• 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Centers
• 9.3. Ambulatory Surgical Centers
• 9.4. Biotechnology & Pharmaceutical Companies
• 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
  • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
  • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
  • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
  • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
  • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
  • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
  • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
  • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
  • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
  • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
  • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
  • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
  • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio